An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Table 2

BEV related adverse events.

Description	Grade 1	Grade 2	Grade 3	Total	Treatment regimen
Likely related to BEV therapy
Hypertension	1	1	0	2	10 mg/kg/2weeks
Epistaxis	0	1	0	1	10 mg/kg/2weeks
Ulceration skin	1	0	1	2	10 mg/kg/2weeks
Hematochezia	1	0	0	1	1 cycle at 5 mg/kg/2weeks;
					9 cycles at 10 mg/kg/2weeks
Subungual hemorrhage	1	0	0	1	10 mg/kg/2weeks
Wound dehiscence	0	1*	0	1	10 mg/kg/2weeks
Abdominal pain syndrome	0	0	1	1	10 mg/kg/2weeks
Total	4	3	2	9

*Occurred more than 2 months after termination of BEV therapy.